ETC-588 (Pfizer).

Article Details

Citation
Copy to clipboard

Doggrell SA

ETC-588 (Pfizer).

Curr Opin Investig Drugs. 2004 Sep;5(9):993-9.

PubMed ID
15503656 [ View in PubMed
]
Abstract

Pfizer, following its acquisition of Esperion Therapeutics in the first quarter of 2004, is developing ETC-588 as a potential acute treatment for ischemia caused by atherosclerosis. Enrollment in phase II trials in patients with acute coronary syndrome is complete.

DrugBank Data that Cites this Article

Drugs